Systemic responses after bronchial aspirin challenge in sensitive patients with asthma.
BACKGROUND
In aspirin-sensitive patients with asthma, bronchial obstruction induced by oral aspirin may be associated with extrabronchial symptoms, suggesting the systemic character of the response.


OBJECTIVE
Go assess potential systemic effects of local aspirin challenge, hemopoietic progenitors were measured in the peripheral blood of challenged patients.


METHODS
In 19 patients with a history of aspirin-induced asthma, placebo-controlled bronchial challenges with lysine-aspirin were performed. Peripheral blood was collected before and then 1 hour and 20 hours after challenge (placebo or aspirin). Using the flow-cytometric method, the numbers of leukocyte (CD34+ cells) and eosinophil (CD34+CD125+ cells) progenitors were determined.


RESULTS
The challenge was positive in 13 patients; 6 patients had isolated local bronchial reaction, and 7 patients developed systemic symptoms (bronchial and extrabronchial). In patients with positive challenge (n = 13), leukocyte progenitors increased significantly at 1 hour and 20 hours after challenge (mean, 0.04% at baseline, 0.066% at 1 hour after challenge, and 0.073% at 20 hours; P < .05). Eosinophil progenitors raised significantly from mean 0.017% before challenge to 0.04% (P < .05) at 20 hours after the challenge. At 20 hours after the challenge, the increase in leukocyte and eosinophil progenitors was observed only in patients with systemic reactions. Positive aspirin challenge was associated with a significant increase in eotaxin 2 serum concentration.


CONCLUSIONS
This study demonstrated that bronchial challenge with aspirin may involve systemic reactions and is associated with mobilization of leukocyte and eosinophil progenitor cells from the bone marrow.
Makowska
Joanna S
JS
Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Grzegorczyk
Janina
J
Bienkiewicz
Barbara
B
Wozniak
Maria
M
Kowalski
Marek L
ML
D000280:Administration, Inhalation; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D001249:Asthma / Q000097:blood / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D001854:Bone Marrow Cells / Q000473:pathology; D001980:Bronchi / Q000503:physiopathology; D054423:Chemokine CCL24 / Q000097:blood; D018925:Chemokines / Q000097:blood; D016207:Cytokines / Q000097:blood; D004342:Drug Hypersensitivity / Q000150:complications; D004804:Eosinophils / Q000473:pathology; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count; D007962:Leukocytes / Q000473:pathology; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D013234:Stem Cells / Q000473:pathology; D015854:Up-Regulation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D054423:Chemokine CCL24; D018925:Chemokines; D016207:Cytokines; D008239:Lysine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate